4547:TYO
Kissei Pharmaceutical Co Ltd
3 695,00 JP¥
0,00%
(0,00) 1D
8 հոկ, 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 710 JP¥
High
3 720 JP¥
Low
3 670 JP¥
Mkt. cap
170,66 մլրդ
Avg. vol.
69,62 հզր
Volume
89,40 հզր
Dividend
3,25%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
10,95
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
Open
3 710 JP¥
High
3 720 JP¥
Low
3 670 JP¥
Mkt. cap
170,66 մլրդ
Avg. vol.
69,62 հզր
Volume
89,40 հզր
Dividend
3,25%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
10,95
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Simply Wall Street
·
6 րոպե առաջ
Zscaler (ZS) Could Be 15% Undervalued Following Reaffirmed 2027 Guidance
ChartMill
·
39 րոպե առաջ
Exploring the top movers within the dow jones index during today's session.
Deadline
·
2 ժամ առաջ
Skydance Shares Rebound After David Ellison And Top Execs Ring Opening Bell At New York Stock Exchange
Yahoo Finance
·
2 ժամ առաջ
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 հզր
Founded09 օգս, 1946 թ.
HeadquartersՄացումոտո, Nagano, Ճապոնիա
Sector-
Websitekissei.co.jp